The benefit-risk assessment, in English Benefit-Risk Assessment, compares the expected or observed therapeutic benefits of a medicinal product or medical device in a structured manner with its risks and the remaining uncertainties. The question is never generally whether a product is “good”, but always what the ratio of benefit to risk is for a specific indication, population and application context. As the supporting criterion for authorization and conformity decisions, it is continually updated throughout the entire product lifecycle. <\/p>\n
Prior to the authorization of a medicinal product, quality, safety and efficacy are not assessed separately, but in context. The benefit side includes clinically relevant endpoints, extent and duration of the effect, robustness of the evidence and the available treatment alternatives; the risk side includes nature, frequency, severity, predictability and treatability of adverse effects. How heavily a risk weighs depends on the severity of the disease: a clear therapeutic benefit can bear a serious but controllable risk, a minor benefit cannot. Since both sides are assessed relatively, the reference to comparison therapy and standard of care is part of it. <\/p>\n
In addition to the known risks, the uncertainties of the data must be explicitly stated: a limited sample size, a short follow-up period, missing data for special patient groups or inconsistent subgroup results. Frequently, submissions fail due to an unstructured narrative that describes benefits and risks but reveals neither a traceable weighting nor a justification for the conclusion. A coherent chain of argumentation is expected, which explains, for example, why a safety risk remains acceptable given a high medical need or effective risk minimization measures. <\/p>\n
The assessment does not end with authorization. Spontaneous reports, literature, registries and post-authorization safety studies refine risks or change the transferability of an observed benefit. The Periodic Safety Update Report provides an integrated analysis of new findings at fixed intervals against the background of the cumulative data, while the risk management plan documents risks, missing information and minimization measures. Consequences may include changes to the product information, requirements for further studies or, in the most extreme case, suspension and withdrawal of the authorization; conversely, every variation application must be reviewed to determine whether new indications or safety findings shift the balance. <\/p>\n
Assessment is predominantly qualitative, supported by clinical plausibility, consistency of the data and clinical relevance. Quantitative methods are available for complex decisions: structured benefit-risk models, multi-criteria decision analysis or weighted benefit-risk tables that explicitly weigh individual criteria against each other. Verifiability depends less on the method than on disclosure of assumptions, sensitivity analyses and a consistent approach to uncertainty. If material gaps remain, a conditional authorization with the requirement to submit missing data may be considered. <\/p>\n
For medicinal products, benefits also include quality of life, treatment adherence and patient-reported endpoints. For medical devices, Article 2(24) of Regulation (EU) 2017\/745 defines the benefit-risk determination as an analysis of all assessments of benefits and risks that may be relevant to the intended purpose specified by the manufacturer. Here, greater weight is given to the clinical benefit in the healthcare context, the safety performance over the product lifetime and usability. This is evidenced by the clinical evaluation under Article 61 and Annex XIV, including clinical follow-up; the determination is reviewed in the conformity assessment procedure by the Notified Body. <\/p>\n
The regulatory benefit-risk assessment must not be confused with the benefit assessment under reimbursement law. It answers only whether a favorable benefit-risk ratio exists and continues to exist for the intended use, and is therefore part of authorization or conformity assessment, supervision and pharmacovigilance. Any available safety and efficacy information is used, including experience from routine clinical practice. <\/p>\n
The benefit assessment under Section 35a SGB V, by contrast, serves social law and health economic purposes: it assesses an additional benefit compared with an appropriate comparator therapy and does not replace the authorization decision. A product may therefore be authorized while additional benefit, comparator therapy and reimbursement conditions are decided separately. Equating the two levels regularly leads to false expectations in study planning, dossiers and communication. <\/p>\n
For medical devices, Article 2(53) MDR defines the narrower concept of clinical benefit as a positive impact on a person’s health, measured by meaningful, patient-relevant clinical outcomes including diagnostic outcomes, or as a positive impact on patient management or public health. Clinical benefit is therefore a component of the Clinical Evaluation as an MDR process and must correspond to the intended purpose of a medical device, against which it is weighed as part of the benefit-risk assessment under Annex I MDR. <\/p>\n
The evidence for each benefit and risk statement is generated in clinical trials, which is why this weighing already shapes the development strategy. Endpoints, safety parameters, target population, pre-defined subgroups, observation period and the handling of missing values must fit the decision that will later need to be justified. Article 28 of Regulation (EU) No 536\/2014 already requires, for the authorization of a clinical trial, that the expected benefits justify the foreseeable risks and disadvantages and that this condition is continuously monitored. Ongoing safety data may lead to adjusted inclusion criteria, additional controls or a reassessment by an independent body. <\/p>\n
Full-service CROs such as Mediconomics support the planned generation of the data needed for this weighing: through study design and alignment of the protocol with risk management, through data management and biostatistical analysis of benefit and safety endpoints, through medical assessment of incoming safety information and through medical writing for study reports and submission documents. This ensures that a consistent line of argumentation remains visible from analysis through to periodic safety reports. <\/p>\n
Does the benefit-risk assessment end with authorization?<\/strong><\/p>\n No, it continues with every new safety, efficacy and use-related information. Periodic safety reports, signal evaluations and post-authorization studies can shift the outcome. <\/p>\n What is the purpose of the risk management plan in this assessment?<\/strong><\/p>\n It documents important identified and potential risks as well as missing information and determines which activities will be used to further characterize or minimize them. The requirements for content and format are described in GVP Module V. <\/p>\n Does a favorable benefit-risk ratio automatically mean an additional benefit?<\/strong><\/p>\n No. One is a criterion for authorization and regulatory supervision; the other is the result of an independent assessment for reimbursement decisions. <\/p>\n The benefit-risk assessment, in English Benefit-Risk Assessment, compares the expected or observed therapeutic benefits of a medicinal product or medical device in a structured manner with its risks and the remaining uncertainties. The question is never generally whether a product is “good”, but always what the ratio of benefit to risk is for a specific […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[23],"class_list":["post-6602","glossary","type-glossary","status-publish","hentry","glossary-cat-pharmakovigilanz"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":7,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6602\/revisions"}],"predecessor-version":[{"id":7875,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6602\/revisions\/7875"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6602"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n